Abstract

THROMBOLYTIC EFFECT OF SOME ANTIDIABETIC DRUGS: IN VITRO AND IN SILICO APPROACH.

Mohammad Shah Hafez Kabir, Fahima Zaheed, Md. Rabiul Hossain, Muhammad Abdulla Al Noman, Mahmudul Hasan, Abul Hasanat, Tanvir Ahmad Chowdhury, Mohammed Abu Sayeed, Kazi Ashfak Ahmed Chowdhury*

Abstract

present study aims to investigate the thrombolytic effect of some antidiabetic drugs by in vitro clot lysis method and in silico molecular docking used to identify whether these drugs interact with the responsible protein (tissue-type plasminogen activator). In vitro clot lysis model was used to observe the thrombolytic effect of Glibenclamide, Metformin hydrochloride, Sitagliptin phosphate and Vildagliptin drugs, where they exhibited 46.61 ± 2.84%, 43.89 ± 3.41%, 24.45 ± 2.62 % and 35.89 ± 3.57 % clot lysis, respectively. Reference drug streptokinase exhibited 78.70±0.92% clot lysis. A wide range of docking score found during molecular docking by CPI server. Glibenclamide, Metformin hydrochloride, Sitagliptin phosphate and Vildagliptin drugs showed the docking score -8.6, -4.9, -3.8 and -7.3, respectively. Glibenclamide possessed highest clot lysis effect and also showed best docking score among the antidiabetic drugs, where Sitagliptin phosphate exhibited the opposite. But results of Metformin hydrochloride and Vildagliptin were different compare with the other drugs result. Though Metformin hydrochloride showed higher clot lysis (43.89 ± 3.41%) effect than Vildagliptin, but in in silico molecular docking method, Vildagliptin showed well docking score over Metformin hydrochloride. Further in vivo investigation need to identify the thrombolytic effect of these antidiabetic drugs and also require making out the mechanism of them as thrombolytic agents.

Keywords: Antidiabetic drugs, PASS prediction, Molecular docking, Glibenclamide, Metformin hydrochloride.